Eli Lilly and Comp. (LLY) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Understanding Accounting and Bookkeeping Services for Business Success

June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success

Every successful business relies on accurate financial records. From managing cash flow to ensuring compliance with tax regulations, reliable accounting and bookkeeping services…
How much does a Turkish passport cost?

May 27, 2025 How much does a Turkish passport cost?

Turkish citizenship comes with numerous benefits. Once granted, a foreigner can enter 126 countries visa-free, enjoy high-quality healthcare and favorable tax regimes, and…
How Measurement and Mix Modeling Drive Better Business Decisions

May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions

In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
Are you making these mistakes when analyzing candlestick patterns?

May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?

Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…

Eli Lilly and Comp. (LLY) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: June 22, 2025 (01:59)

Sector: Healthcare

The share price of Eli Lilly and Company (LLY) now

Latest session on the 20th of June for
Eli Lilly and Company is negative
Trading Volume: 6210647
Open: 786 /  High: 786 /  Low: 755.56
Current value: $762.73
What analysts predict: $955.31
52-week High/Low: $967.27 / $675.71
50-Day Moving Average: $784.3 — resistance level today
200-Day Moving Average: $834.68 — resistance level today

News Impact Analyzer

Full report
This Week
Bullish Impact: 5 News: 15 (10/3/2)
Previous Week
Bullish Impact: 5 News: 4 (2/2/0)
Two Weeks Ago
Bullish Impact: 5 News: 3 (3/0/0)
Three Weeks Ago
Bullish Impact: 1.13 News: 4 (1/2/1)

Analysts predictions

Full report
This Week
Bullish Opinions: 4 (4/0/0)
Previous Week
Bullish Opinions: 1 (1/0/0)
Two Weeks Ago
Bullish Opinions: 1 (1/0/0)
Three Weeks Ago
Neutral Opinions: 1

Analyzing the Most Important LLY news

Major Deals Stir the Market: Eli Lilly Acquires Verve Therapeutics!

Jun 21, 2025
Trend: Bullish
Influence: 8
Eli Lilly's $1.3B acquisition of Verve Therapeutics highlights strategic investment in gene-editing technology, reinforcing its innovation-driven profile. This move could enhance its pipeline and revenues, boosting investor confidence. The strategic fit aligns with strong market trends, potentially pushing the stock higher in the short-to-medium term and positioning Eli Lilly as a leader in precision medicine.

Eli Lilly's Orforglipron Impresses in Phase 3 Trial with Weight Loss and Diabetes Control

Jun 21, 2025
Trend: Bullish
Influence: 8
The successful Phase 3 trial results for orforglipron highlight Eli Lilly’s strong position in the lucrative weight loss and diabetes treatment markets. With further trial readouts and regulatory filings planned, the news solidifies confidence in the drug’s potential, likely boosting investor sentiment and stock prices significantly in the near term.

Major Weight Loss Drug Trials Set to Shake Up the Obesity Market

Jun 20, 2025
Trend: Bullish
Influence: 8
Eli Lilly's upcoming Phase 3 results for orforglipron could significantly impact its obesity drug pipeline. The weight loss market is hot, and positive results would reinforce LLY's leadership. This high-profile ADA presentation has strong potential to boost investor confidence and LLY's stock price if the data aligns with expectations.

Historical and forecast chart of Eli Lilly and Comp. stock

The chart below shows the historical price of Eli Lilly and Comp. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Eli Lilly and Comp. stock price can be found in the table below.

Long-term forecasts by years.

Eli Lilly and Company Analysts predictions review

Eli Lilly's strategic acquisition of Verve Therapeutics and its entry into the cardiovascular gene therapy sector highlight a clear commitment to innovation-led growth. The investment in GalNAc PCSK9 gene editing positions Lilly in a high-growth, high-potential market with transformative therapeutic applications. While regulatory risks and clinical success are key uncertainties, the acquisition enhances its R&D pipeline and diversifies revenue opportunities. Investor sentiment remains bullish, driven by future growth prospects, pipeline advancements, and prudent capital deployment. Near-term stock performance will depend on trial data and integration synergies, with long-term potential reinforced by the cardiovascular market's expansion.

Eli Lilly's Strategic Move: Evaluating the GalNAc PCSK9 Gene Editing Acquisition

Trend: Bullish
Jun 17, 2025

Eli Lilly’s acquisition ties directly to the transformative potential of the GalNAc PCSK9 gene editing program, reflecting its ambition to expand its innovative footprint in cardiovascular treatments. The author points out that this program signals an entry into a competitive precision medicine market, with high reward potential but inherent execution risks.

Impact of Gene Editing on Eli Lilly’s Growth Trajectory

The strategic focus on PCSK9 gene editing could accelerate revenue growth in a high-value therapeutic area, especially if initial trials demonstrate compelling efficacy and safety. However, it also introduces uncertainty, as clinical success is pivotal, and regulatory hurdles could delay market entry.

The acquisition aligns with Eli Lilly’s broader objective to strengthen its pipeline, which bolsters investor confidence in its capacity for innovation-led growth. According to the author, this could positively influence valuation multiples, provided the program meets development milestones.

In the near term, market sentiment toward the stock will likely hinge on updates regarding early-stage data and integration synergies. The author’s thesis emphasizes that these dynamics, along with broader market conditions, could either amplify or temper the stock's price action.


Analyst: Terry Chrisomalis
( Followers: 13457
Articles: 1488 )

Eli Lilly's Strategic Move: Verve Therapeutics Acquisition and Its Impact on LLY Growth Potential

Trend: Bullish
Jun 17, 2025

Eli Lilly's acquisition of Verve Therapeutics signifies a pivotal strategic initiative aimed at cementing its foothold in the cardiovascular treatment sector. By focusing on innovative gene-editing technologies to permanently lower cholesterol levels, this move aligns with growing demand for advanced and long-term healthcare solutions, indicating a strong avenue for future revenue expansion.

Key Factors Shaping LLY's Near-Term Stock Performance

The integration of Verve's cutting-edge therapeutic pipeline enhances Eli Lilly's R&D portfolio and competitive positioning in the biotech space. This development could drive investor confidence, especially as the cardiovascular market is poised for continued growth.

Potential regulatory hurdles and timelines for clinical trials remain critical risks that could moderate immediate market enthusiasm. Nevertheless, the prospect of long-term benefits from exclusive proprietary technologies positions LLY for sustained innovation-driven growth.

Lastly, the transaction underscores Eli Lilly's strategic capital deployment, highlighting prudent investment in high-growth opportunities. Such moves could foster shareholder confidence, particularly among institutional investors seeking exposure to transformative healthcare advancements.


Analyst: Edmund Ingham
( Followers: 13399
Articles: 1040 )

Eli Lilly's Strategic $1.3B Investment in Cardiovascular Breakthroughs: Implications for LLY Stock

Trend: Bullish
Jun 17, 2025

Eli Lilly's $1.3 billion investment in Verve Therapeutics underscores its commitment to the rapidly advancing cardiovascular gene therapy market. This move positions Lilly as a frontrunner in addressing significant unmet needs in cardiovascular diseases, with substantial long-term growth potential. The partnership could accelerate drug discovery timelines and enhance diversified revenue streams for the company.

Key Drivers Affecting Eli Lilly's Stock Price

The financial collaboration reflects not just an equity investment but also milestone-based success payments, fostering alignment of incentives between the two companies. This approach limits immediate risk to Lilly while enabling exposure to disruptive biotechnological advancements, which is a positive factor for investor confidence in near-term valuation stability.

The cardiovascular gene therapy space is projected to see exponential growth, bolstered by increasing clinical adoption of advanced genetic editing technologies like CRISPR. By strategically aligning with Verve, Lilly taps into an area with high therapeutic relevance and scalability, likely reinforcing bullish sentiment among institutional investors.

Additionally, ignoring short-term headline risks tied to biotech volatility, this deal highlights Lilly's long-term innovation strategy. Such sustained R&D efforts solidify its competitive position while counterbalancing possible margin compression in other product categories.


Analyst: Stephen Ayers
( Followers: 8462
Articles: 910 )
Jun 05, 2025
Eli Lilly: Capturing Growth Potential with Weight Loss Innovations
Trend: Strong Bullish

Weight loss innovations have emerged as a transformative growth driver for Eli Lilly, with the company's advancements in obesity treatments like Mounjaro positioning it as a market leader in this multi-billion-dollar sector. The author emphasizes that the strong demand and regulatory approvals could lead to significant revenue expansions, potentially redefining the company's core business segments.

Pipeline strength further reinforces Eli Lilly's growth prospects. With promising late-stage drug candidates targeting areas like diabetes, oncology, and neuroscience, the company is strategically diversifying its portfolio, which could act as a robust hedge against market volatility and enhance long-term valuation.

Strategic Market Leadership

Eli Lilly's strategic positioning in the obesity and diabetes treatment markets underscores its market leadership and pricing power. According to the author, the potential for global healthcare policy shifts supporting obesity treatments could further amplify demand and solidify its first-mover advantages.

Valuation metrics and earnings momentum also support a bullish view on the stock. As the author notes, strong earnings growth coupled with expanding operating margins highlights operational efficiency, while valuation relative to peers suggests further upside, especially if weight-loss therapies exceed market expectations.

Analyst: Edmund Ingham
( Followers: 13354
Articles: 1024 )
Jun 02, 2025
Eli Lilly's Strategy in Pain Management: Evaluating NaV1.8 Pathway Investments
Trend: Bullish

Recent advancements in targeting the NaV1.8 pathway for pain management reflect Eli Lilly's robust focus on innovation within specialized therapeutics. Leveraging this approach, the company is positioning itself as a leader alongside Vertex Pharmaceuticals, indicating a commitment to addressing unmet medical needs in a competitive market. As noted by the author, success in this domain could potentially create a durable competitive advantage in an area of high medical and commercial value.

Implications for Eli Lilly’s Stock Valuation

The success of pipeline assets targeting the NaV1.8 pathway could translate to a significant long-term revenue stream. However, this progress also carries execution risks, such as clinical trial results and FDA approval hurdles, which may introduce short-term volatility. Additionally, the company's strategic partnerships and investments in cutting-edge therapies signal disciplined capital allocation aimed at high-reward opportunities. The outcome of these incoming clinical milestones will likely serve as key catalysts affecting near-term stock movements.

Broader market dynamics, including increasing competition in the pain management space, could act as an external moderating force on profitability. It remains essential for Eli Lilly to demonstrate leadership through both efficacy data and commercialization strategies to sustain investor confidence. The author underscores these dynamics, highlighting the potential for both risk and reward tied to the company’s innovative focus.

Analyst: ELAM1 Consulting
( Followers: 47
Articles: 7 )
May 27, 2025
Eli Lilly Faces Market Pressure Despite Novo Nordisk’s Setbacks
Trend: Neutral

Eli Lilly (LLY) currently faces challenges in sustaining its competitive edge within the pharmaceutical market, particularly in the wake of Novo Nordisk’s recent struggles. The author notes that while Novo Nordisk’s issues could have provided a tailwind for LLY’s stock performance, prevailing concerns about valuation metrics and market saturation have tempered investor optimism.

Valuation Concerns and Competitive Dynamics

The high valuation of Eli Lilly’s stock, which trades at a premium to its peers, has raised questions about its near-term growth potential. The author underscores that without a significant catalyst for growth, such elevated pricing could limit upside opportunities and possibly attract profit-taking in the short term.

Another key factor highlighted is the competitive landscape in the GLP-1 agonist market, where both Eli Lilly and Novo Nordisk are dominant players. While Novo Nordisk’s struggles could reduce competition, Eli Lilly’s ability to capitalize depends on maintaining innovation and gaining further market share, which remains uncertain in the immediate future.

Finally, the pipeline of new product launches, which is often a key growth driver in the pharmaceutical sector, appears to lack near-term revolutionary breakthroughs. As the author points out, this has made it difficult for investors to justify the current elevated valuations absent a clear path to accelerating revenue growth.

Analyst: Daniel Schönberger
( Followers: 12987
Articles: 852 )
May 16, 2025
Eli Lilly’s Expanding Obesity Drug Portfolio: Key Catalysts for Long-Term Growth
Trend: Bullish

The development of Eli Lilly's obesity drug pipeline, with ambitions extending beyond Zepbound, represents a pivotal growth avenue for the company. By addressing a broader spectrum of obesity-related conditions and positioning itself at the forefront of a rapidly expanding market, LLY is set to capitalize on increasing global demand for effective treatments. The author emphasizes the strategic importance of this segment as a potential driver of long-term revenue and margin expansion.

Market Dynamics and Strategic Innovation

LLY's innovative approach within its pipeline underscores the company's commitment to differentiation through clinical advancement. By leveraging proprietary technology and aiming for superior efficacy profiles, the author argues that Eli Lilly is creating a competitive edge that could enhance investor confidence and sustain premium valuation multiples in the near to medium term.

Additionally, the pipeline's diversification mitigates risk by reducing dependency on any single blockbuster drug. This balance not only reinforces financial stability but also signals management's strategic foresight, an element that may positively influence institutional investor sentiment.

The regulatory environment, as noted, could play a dual role. The approval of new treatments would accelerate market penetration, but any unanticipated delays or setbacks may weigh on short-term performance. Still, the overall outlook remains favorable given Eli Lilly's track record of navigating complex regulatory landscapes.

Analyst: Terry Chrisomalis
( Followers: 13403
Articles: 1466 )
May 03, 2025
Eli Lilly's Strategic Recovery Positions the Stock for Near-Term Upside
Trend: Bullish

Eli Lilly's stock performance has recently faced downward pressure due to factors such as regulatory challenges and broader market volatility. The author's analysis underscores that the company's strategic pipeline recovery, coupled with its strong presence in the high-demand pharmaceutical sector, provides a foundation for near-term growth despite temporary setbacks.

Key Drivers of Upside Potential

The author highlights Eli Lilly's diversified therapeutic portfolio and promising clinical trials as critical to reclaiming investor confidence. Advanced-stage developments in areas such as diabetes and cancer treatments could lead to renewed revenue momentum, offering significant upside potential for the stock.

Continued demand for innovative treatments and a resilient research pipeline solidify the company's competitive position in its sector. The author further notes Eli Lilly's historical ability to navigate periods of turbulence and deliver shareholder value, suggesting strong management execution.

Operational headwinds, such as pricing pressures and competition, are acknowledged; however, these factors are viewed as temporary hurdles rather than long-term impediments. The author's outlook remains optimistic, reinforced by consistently improving fundamentals.

Analyst: Juxtaposed Ideas
( Followers: 13689
Articles: 1353 )
May 03, 2025
Eli Lilly: Strategic Growth and Innovations Offer Long-Term Benefits
Trend: Bullish

Eli Lilly's robust pipeline of innovative drugs serves as a critical driver for the company's long-term growth potential. The author notes the near-term catalysts, including highly anticipated developments in diabetes and obesity treatments, which are poised to capture significant market share and enhance revenue streams.

Key Catalysts Driving Confidence in LLY Stock

The company's emphasis on research and development positions it as a leader in addressing high-demand medical conditions. This sustained investment guarantees a competitive edge, as highlighted by the article, contributing to investor optimism.

Eli Lilly's recent earnings growth and consistent performance underscore the resilience of its business model. These aspects reiterate the author's viewpoint that current valuation metrics remain justifiable despite premium pricing.

Management's strategic capital allocation, particularly toward expansion and acquisitions, complements the organic growth initiatives. As the article suggests, this approach aligns with long-term shareholder value creation and mitigates risks associated with over-reliance on single markets.

Analyst: JR Research
( Followers: 41566
Articles: 2587 )
May 01, 2025
Eli Lilly’s Volatile Reaction: CVS Decision on Zepbound and Market Outlook
Trend: Neutral

The exclusion of Zepbound from CVS Health’s formularies is a pivotal financial development, potentially impacting Eli Lilly’s revenue forecasts tied to this specific drug. According to the analysis, the market's reaction appears disproportionate to the scale of this decision in the broader context of Eli Lilly's diversified product portfolio and growth trajectory.

Key Factors Driving Eli Lilly’s Stock Movement

The historical overperformance of Eli Lilly’s stock relative to peers suggests underlying investor confidence in its long-term prospects. However, the 11%+ drop reflects heightened sensitivity to pipeline disruptions and formulary adjustments, signaling that sentiment could see continued volatility.

Despite recent setbacks, Eli Lilly’s robust pipeline, including its innovation in diabetes and obesity treatments, offers a steady stream of growth drivers. The long-term value proposition remains strong as these treatments address high-demand medical needs and demonstrate significant revenue upside potential.

Analyst: IB's Thoughts
( Followers: 1811
Articles: 273 )
Apr 28, 2025
Eli Lilly: Orforglipron Could Propel Growth Amid GLP-1 Demand
Trend: Strong Bullish

Eli Lilly’s development of Orforglipron, a once-daily oral GLP-1 receptor agonist, signifies a critical breakthrough as it addresses a major patient barrier—the inconvenience of injectable treatments. The author emphasizes that this innovation positions Lilly to capture a larger share of the rapidly expanding GLP-1 market, driving substantial growth potential.

The competitive landscape in the obesity and diabetes treatment markets imposes pressure on pharmaceutical companies to innovate. Eli Lilly’s leadership in the GLP-1 category—with products like Mounjaro—suggests its expertise in leveraging clinical efficacy and safety data, as highlighted by the author, further solidifying its competitive edge.

Strategic Market Opportunities

Lilly’s efforts to expand the product pipeline and deepen penetration into high-growth therapeutic markets underline its robust R&D capabilities. According to the author, Orforglipron strengthens the company’s outlook for scaling revenues, potentially translating into enhanced stock performance.

The macroeconomic backdrop, including widespread demand for obesity treatments, is favorably aligned with Eli Lilly’s advancements. The author notes strategic timing as another positive factor, making the company well-positioned to maximize commercial opportunities in the near term.

Analyst: ONeil Trader
( Followers: 9139
Articles: 895 )
Apr 25, 2025
Eli Lilly: Driving Growth Through Orforglipron and Strategic Momentum in Q1
Trend: Strong Bullish

Eli Lilly's prospects are significantly bolstered by the anticipated success of Orforglipron, a pivotal drug in their diabetes portfolio. Its potential to capture substantial market share in the growing GLP-1 market positions the company for both near- and long-term revenue expansion. The author highlights this asset as a cornerstone for sustained growth, supported by a well-differentiated product profile that enhances competitive resilience.

Key Catalysts Supporting Stock Momentum

Furthermore, Eli Lilly's existing pharmaceutical lineup continues to outperform, particularly its burgeoning portfolio in oncology and immunology. The strong pipeline and recent regulatory approvals point to robust earnings growth potential, which the author believes could act as a near-term catalyst for the stock.

Operationally, the company maintains a solid financial base with improving gross margins and disciplined cost management. Combined with incremental revenue growth drivers like Orforglipron, these operational efficiencies could reflect positively in upcoming earnings reports, fueling investor confidence.

Finally, macroeconomic tailwinds such as expanding global healthcare demand and the company’s focus on innovation align with long-term growth trends. These factors not only validate Eli Lilly’s current valuation but also strengthen its position in the high-growth pharmaceutical sector.

Analyst: BioCGT Investor
( Followers: 975
Articles: 50 )

Comprehensive Analysis of Eli Lilly and Comp. (LLY) Stock Market Performance


Our multifaceted analysis of Eli Lilly and Comp.'s stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Eli Lilly and Comp. stock?
  • When should I record a loss on Eli Lilly and Comp. stock?
  • What are analysts' forecasts for Eli Lilly and Comp. stock?
  • What is the future of Eli Lilly and Comp. stock?

We forecast Eli Lilly and Comp. stock performance using neural networks based on historical data on Eli Lilly and Comp. stocks.

Eli Lilly and Company is an American pharmaceutical company. It was founded in 1876 in Indianapolis, Indiana, where its headquarters are still located. It is known as the first company to start the industrial production of insulin (in 1923). The company operates in two areas: medicines for humans and veterinary medicines (a division of Elanco). The company’s products are sold in 120 countries.

www.lilly.com

Eli Lilly and Company News influencing stock rates

As of now, Panda has combed through 26 news items directly related to LLY from the last 30 days. Out of these, 16 clearly showcase a bullish trend, while 3 display bearish tendencies, and 7 events are neutral.

Based on an analysis of the most important news from the last 30 days affecting LLY shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.

The news analyzed fell within the period from May 22, 2025, to Jun 21, 2025.

βeta
Jun 20, 2025

Fed Rate Cut Looms, Obesity Drugs Boost LLY, Aflac Faces Cybersecurity Challenge

Trend: Bullish
Influence: 8
Eli Lilly gains a bullish outlook as cardiologists recommend weight-loss drugs like tirzepatide to prevent cardiovascular events. This clinical endorsement highlights the expanding market for obesity treatments, signaling strong revenue growth potential. With health trends increasingly favoring GLP-1 drugs, LLY's stock is likely to improve in the short-to-medium term as demand and investor confidence grow.
Jun 20, 2025

Obesity Drugs Gain Momentum as Key Heart Disease Preventative – A Boost for Eli Lilly

Trend: Bullish
Influence: 8
The ACC's endorsement of obesity drugs for heart disease prevention is a major catalyst for companies like Eli Lilly, which markets tirzepatide. This recognition opens doors for wider insurance coverage and boosts demand, solidifying LLY's position in a lucrative market. This news could significantly elevate investor sentiment and drive the stock price higher in the near term.
Jun 19, 2025

Biotech M&A Revival Hinges on Interest Rates and Drug Reforms

Trend: Neutral
Influence: 6
The news highlights potential catalysts for M&A, such as lower interest rates and regulatory clarity. However, its immediate impact on LLY is neutral, as deal-making activity remains uncertain. Long-term, increased M&A could benefit LLY through potential partnerships or acquisitions, but short-term price movements are unlikely to be heavily influenced by this single news item.
Jun 19, 2025

FDA Appoints Prasad as Chief Medical and Scientific Officer Amid Restructuring

Trend: Neutral
Influence: 3
The news is focused on internal FDA personnel changes with no direct link to Eli Lilly (LLY). Though regulatory leadership can influence drug approval processes, the immediate impact on LLY's stock is limited. A slight indirect effect may arise from broader regulatory implications, but no significant short-term impact on LLY's stock is expected.
Jun 19, 2025

Skye Bioscience Challenges Eli Lilly's GLP-1 Dominance with Nimacimab Updates

Trend: Neutral
Influence: 4
While Skye Bioscience's nimacimab has potential to disrupt the obesity market, it's still in phase 2 trials and lacks immediate threat to Eli Lilly's established GLP-1 products like Mounjaro. Interest in alternative treatments is noteworthy but limited short-term impact on LLY stock is expected unless nimacimab showcases superior results in upcoming announcements.
Jun 18, 2025

Bariatric Surgery Outperforms Eli Lilly’s GLP-1 Drugs in Weight Loss Battle

Trend: Bearish
Influence: 7
With bariatric surgery demonstrating significantly superior weight loss results compared to GLP-1 drugs, this study could dampen investor confidence in Eli Lilly’s position within the obesity drug market. As weight loss efficacy is critical for market performance, this news may cause short-term pressure on LLY’s stock price, especially if competitors can capitalize on alternative methods.
Jun 18, 2025

Scholar Rock and Lilly Combo Shows Promising Weight Loss with Muscle Preservation

Trend: Bullish
Influence: 7
The positive mid-stage trial results for Scholar Rock's asset paired with Lilly’s tirzepatide enhance the drug's appeal by addressing lean mass preservation—a common concern with GLP-1 therapies. This breakthrough could expand tirzepatide's market potential, supporting a bullish outlook for LLY. However, the influence is moderate as the trial is still in early-to-mid stages.
Jun 17, 2025

FDA's Makary Pushes AI Integration to Fast-Track Drug Reviews

Trend: Bullish
Influence: 7
The FDA's focus on modernizing drug reviews and embracing AI tools bodes well for Eli Lilly (LLY). Faster approvals can accelerate the commercialization of their therapies, boosting revenues. This positive regulatory sentiment, along with initiatives like the national priority voucher program, may raise market confidence in LLY's pipeline potential and near-term growth prospects.
Jun 17, 2025

FDA's New Voucher System to Slash Drug Review Times to 2 Months

Trend: Bullish
Influence: 8
Accelerated FDA approvals can bring LLY’s pipeline drugs to market faster, strengthening revenue growth potential. This initiative aligns with LLY’s innovative approach in drug development, creating a favorable environment for investors. Enhanced efficiency and prioritized reviews could result in quicker monetization of key therapies, potentially boosting stock performance in the near future as innovation cycles shorten.
Jun 17, 2025

White House Considers Limits on Pharma Ads, Targeting $10 Billion Market

Trend: Bearish
Influence: 7
Tighter restrictions on direct-to-consumer pharma ads could significantly impact marketing strategies, raising costs for companies like Eli Lilly (LLY). If implemented, these measures might reduce outreach effectiveness and hurt sales growth, particularly for heavily advertised therapies. While discussions are ongoing, the uncertainty casts a bearish shadow, reflecting a moderately strong influence on LLY's near-term stock performance.

Trending Themes in the Healthcare Sector

Eli Lilly and Comp. daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 23 759.88 749.62 774.69 3.35
Jun 24 761.02 749.15 774.03 3.32
Jun 25 748.92 739.26 753.41 1.91
Jun 26 750.94 734.49 762.65 3.83
Jun 27 750.71 739.68 767.60 3.78
Jun 28 770.76 763.13 785.33 2.91
Jun 29 761.97 745.51 776.83 4.20
Jun 30 769.29 754.28 784.29 3.98
Jul 01 753.82 737.77 764.00 3.56
Jul 02 752.69 748.18 769.85 2.90
Jul 03 743.21 729.16 750.79 2.97
Jul 04 751.90 737.24 760.02 3.09
Jul 05 753.48 738.34 764.79 3.58
Jul 06 743.31 731.27 757.58 3.60
Jul 07 739.07 732.20 756.59 3.33
Jul 08 735.31 721.63 740.82 2.66
Jul 09 727.58 719.94 735.66 2.18
Jul 10 738.50 732.07 746.92 2.03
Jul 11 739.83 722.52 755.14 4.52
Jul 12 722.74 717.53 734.01 2.30
Jul 13 725.12 709.68 734.26 3.46
Jul 14 711.42 695.84 723.37 3.96
Jul 15 715.47 698.52 722.77 3.47
Jul 16 704.74 688.46 715.10 3.87
Jul 17 698.40 692.74 708.25 2.24
Jul 18 718.09 704.52 725.85 3.03
Jul 19 698.70 685.71 713.17 4.00
Jul 20 688.85 682.65 703.53 3.06
Jul 21 670.25 665.63 676.29 1.60
Jul 22 669.05 653.79 680.09 4.02

Eli Lilly and Comp. Daily Price Targets


Eli Lilly and Comp. Stock Forecast 06-23-2025.

Forecast target price for 06-23-2025: $759.88.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.237%.
Pessimistic target level: 749.62
Optimistic target level: 774.69

Eli Lilly and Comp. Stock Forecast 06-24-2025.

Forecast target price for 06-24-2025: $761.02.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.215%.
Pessimistic target level: 749.15
Optimistic target level: 774.03

Eli Lilly and Comp. Stock Forecast 06-25-2025.

Forecast target price for 06-25-2025: $748.92.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 1.879%.
Pessimistic target level: 739.26
Optimistic target level: 753.41

Eli Lilly and Comp. Stock Forecast 06-26-2025.

Forecast target price for 06-26-2025: $750.94.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.692%.
Pessimistic target level: 734.49
Optimistic target level: 762.65

Eli Lilly and Comp. Stock Forecast 06-27-2025.

Forecast target price for 06-27-2025: $750.71.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.638%.
Pessimistic target level: 739.68
Optimistic target level: 767.60

Eli Lilly and Comp. Stock Forecast 06-28-2025.

Forecast target price for 06-28-2025: $770.76.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.827%.
Pessimistic target level: 763.13
Optimistic target level: 785.33

LLY (LLY) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jul. 786.94 739.88 837.07 11.61
Aug. 752.16 722.82 819.63 11.81
Sep. 754.11 724.70 831.56 12.85
Oct. 681.57 634.61 699.29 9.25
Nov. 603.60 587.90 626.35 6.14
Dec. 598.10 546.01 630.76 13.44

Eli Lilly and Comp. forecast for this year


Eli Lilly and Comp. Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $786.941. Pessimistic: $739.88. Optimistic: $837.07


Eli Lilly and Comp. Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $752.159. Pessimistic: $722.82. Optimistic: $819.63


Eli Lilly and Comp. Stock Prediction for Sep 2025

An uptrend is forecast for this month with an optimal target price of $754.114. Pessimistic: $724.70. Optimistic: $831.56


Eli Lilly and Comp. Stock Prediction for Oct 2025

An downtrend is forecast for this month with an optimal target price of $681.568. Pessimistic: $634.61. Optimistic: $699.29


Eli Lilly and Comp. Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $603.597. Pessimistic: $587.90. Optimistic: $626.35


Eli Lilly and Comp. Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $598.104. Pessimistic: $546.01. Optimistic: $630.76



Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 639.31 611.06 662.59 7.78
Feb 656.77 597.00 676.40 11.74
Mar 625.18 582.92 664.19 12.24
Apr 692.63 620.60 756.56 17.97
May 677.33 644.75 728.40 11.48
Jun 705.50 633.05 770.62 17.85
Jul 730.27 701.79 784.38 10.53
Aug 700.84 666.22 739.10 9.86
Sep 717.24 654.76 772.25 15.21
Oct 710.71 669.13 740.27 9.61
Nov 713.48 667.10 778.41 14.30
Dec 668.96 617.65 692.44 10.80

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 643.74 611.10 673.87 9.31
Feb 645.41 603.46 673.10 10.35
Mar 563.19 547.81 601.99 9.00
Apr 555.87 508.90 588.38 13.51
May 546.47 495.32 602.60 17.80
Jun 525.87 477.33 555.27 14.04
Jul 529.97 509.99 573.38 11.05
Aug 583.71 526.04 607.24 13.37
Sep 633.04 577.07 657.72 12.26
Oct 610.82 553.64 673.55 17.80
Nov 540.94 524.76 564.85 7.10
Dec 496.64 461.77 519.88 11.18

Eli Lilly and Comp. information and performance

Eli Lilly and Comp. Address

LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US

Market Capitalization: 670 716 527 000 $

Market capitalization of the Eli Lilly and Company is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of LLY shares in the company outstanding by the market price of one share.

EBITDA: 22 003 300 000 $

EBITDA of Eli Lilly and Comp. is earnings before interest, income tax and depreciation of assets.

PE Ratio: 60.99

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.146

Price/earnings to growth

DPS: 5.4

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.008

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 12.25

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.234
Quarterly Revenue Growth YOY: 0.452
Trailing PE: 60.99

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 34.25

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 14.41

Enterprise Value (EV) /Revenue

EV To EBITDA: 43.38

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 897736000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Eli Lilly and Comp. (LLY) stock dividend

Eli Lilly and Comp. last paid dividends on 05/16/2025. The next scheduled payment will be on 06/10/2025. The amount of dividends is $5.4 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Eli Lilly and Comp. Stock)

Should I Buy Eli Lilly and Comp. Shares in 2025 year?

The maximum forecasted share price for next year is $730.27, Это на 32.46$ меньше чем текущая цена акций. Инвестируя сегодня в акции Eli Lilly and Comp. на срок 1 год вы получите убыток в размере 4.26%. With an investment horizon of up to two years, the target share price is 645.41$. Убыток: 15.38% (-117.32$ на каждую акцию).

Does Eli Lilly and Comp. pay dividends?

No, it does not

Which economic sector do Eli Lilly and Comp.'s shares belong to?

Eli Lilly and Comp.'s shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Eli Lilly and Comp.'s shares?

You can view all the stocks that are part of the same sector as Eli Lilly and Comp.'s shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.